drugset / Trial / NCT03807921
Anticoagulation for Aortic Bioprosthesis (ANTIPRO)
Phase 4
Completed
140 enrolled
Instituto Nacional de Cirugia Cardiaca, Uruguay
Universidad de la Republica · collab
RandomizedParallel-groupSingle-blindTreatment
Summary
This study evaluates the clinical and hemodynamic outcome in patients after aortic valve replacement. Half of the patients will receive warfarin + aspirin and the other half will receive only aspirin. The investigators will focus mainly on early bioprosthesis degeneration.
Timeline
- Start
- 2019-01-01
- Primary completion
- 2019-12-30
- Completion
- 2019-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Warfarin | Small molecule | 5 mg | Oral |
| Background | Aspirin | Small molecule | 100 mg | — |
| Background | Aspirin | Small molecule | 325 mg | — |